Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Carvina Capital: Medline’s IPO Could Top Charts

Healthcare supply chain flotation, valuation scenarios, liquidity appetite, S-1 filing signals, private equity exit context and institutional demand for large, cash-generative listings

SINGAPORE, SG / ACCESS Newswire / October 11, 2025 / In the current issuance window, Carvina Capital Pte. Ltd. highlights Medline Industries as the potential pace-setter for US new issues, with a proposed float that targets approximately $5 billion in gross proceeds at launch and contemplates an equity valuation near $50 billion at pricing. The timetable under discussion points to a public filing in the coming weeks and first trading shortly thereafter, subject to market conditions and regulatory confirmation.

Scale and essential product coverage continue to anchor institutional focus. Over the latest reported financial year, Medline records net sales of $25.5 billion and a global workforce above 43,000 at the latest disclosure, indicators that support visibility on cash generation and distribution reach. For Peter Jacobs, Director of Private Equity at Carvina Capital, "scale, liquidity and clear earnings visibility in the current quarter concentrate institutional interest in healthcare issuance."

Private equity context shapes valuation discourse. Medline's capital structure reflects a $34 billion buyout in 2021, and a reference equity value near $50 billion implies a 47% uplift since the 2021 acquisition. In Jacobs's words, "a prospective $50 billion equity story set against non-discretionary demand recalibrates the IPO calendar, with investors weighing free cash conversion and the durability of hospital and outpatient volumes."

Sizing alternatives remain in active discussion. Separate scenarios translate to $5.5 billion of primary capital and a corresponding equity value around $55.3 billion at the stated conversion rate, reinforcing the possibility of a lead transaction in the current window for large US listings. As Jacobs frames it, "bookbuilding works best where free float breadth balances post listing stability, since that alignment supports early-session liquidity without compromising operational focus."

Pipeline dynamics provide further context. Healthcare new issues in the present cycle appear limited in number, which channels attention toward sizeable, cash-generative companies with recurring revenue characteristics. Carvina notes that index inclusion potential, securities lending availability and borrow depth also enter portfolio construction decisions for both active and passive mandates. According to Jacobs, "investors look through short-term noise to recurring cash generation, unit economics and distribution resilience over the preceding 12-month period."

Disclosure remains the next determinant of market tone. The forthcoming S-1 is expected to set out use of proceeds, segment performance, capital structure and governance arrangements that inform pricing and allocation decisions. In Jacobs's view, "the S-1 deserves a line-by-line reading before any allocation decision, since formal disclosures, not heuristics, define the baseline for risk assessment."

Operational considerations continue to support the investment case. Medline's logistics footprint, technology architecture and resilience programme, including multi-site distribution capacity and cloud-enabled planning tools, position the business to service hospital, outpatient and long-term care settings across cycles. The underlying demand profile for gloves, gowns, disposables and procedural kits provides repeat purchase dynamics that help smooth revenue over the preceding 12-month period, which many institutions prefer when adjusting exposures into the current quarter.

Risk factors remain part of the assessment. Rates, inflation expectations, policy signals and geopolitics influence buy-side risk budgets through the roadshow period. Execution depends on stable funding markets, clear governance frameworks and disciplined capital deployment. As Jacobs notes, "order books reward clarity on balance sheet priorities, especially where free cash supports prudent deleveraging and focused investment over the next 12-month period."

If the schedule holds, the prospective transaction sets a reference point for healthcare issuance and the broader IPO pipeline in the near term. Carvina continues to assess disclosures, market tone and secondary-market setup through the pricing window, with attention on final sizing, valuation discipline and early trading dynamics.

About Carvina Capital

Carvina Capital Pte. Ltd. (UEN: 201220825D) is a Singapore-based investment firm established in 2012. The firm concentrates on research-driven, long-only strategies in listed equities for institutional and professional investors, while evaluating pathways that could open selected products to retail clients. Its research process and disciplined risk management aim to compound capital across full market cycles. Further information is available at https://carvina.com. Media enquiries: Huacheng Yu, media@carvina.com

Media Contact

Contact Person: Huacheng Yu
Company: Carvina Capital Pte. Ltd.
Email: media@carvina.com
Website: https://carvina.com
Carvina Capital Pte. Ltd.

SOURCE: Carvina Capital Pte. Ltd.



View the original press release on ACCESS Newswire

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  213.04
-1.43 (-0.67%)
AAPL  252.29
+4.84 (1.96%)
AMD  233.08
-1.48 (-0.63%)
BAC  51.28
+0.84 (1.67%)
GOOG  253.79
+1.91 (0.76%)
META  716.91
+4.84 (0.68%)
MSFT  513.58
+1.97 (0.39%)
NVDA  183.16
+1.35 (0.74%)
ORCL  291.31
-21.69 (-6.93%)
TSLA  439.31
+10.56 (2.46%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.